Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTIMATE: Durvalumab + Endocrine Therapy in ER+/Her2- Breast Cancer
NCT02997995Phase 2Completed
- Sponsor
- Unicancer
- Start
- Feb 2017
- Primary completion
- Jul 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of durvalumab in breast cancer, sponsored by Unicancer. Started Feb 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02997995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997995.